Recent News

Trends in Myeloma by Age: Treatment and Outcome Disparities Explored

ARROW Trial: Once- or Twice-Weekly Carfilzomib Plus Dexamethasone in Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone for Transplant-Ineligible Patients With Myeloma

ASTRO 2020: Low-Dose Radiotherapy for Painful Osseous Lesions in Patients With Myeloma

ASTRO 2020: U.S. Trends in Use of Palliative Radiotherapy for Myeloma

Novel Peptide-Drug Conjugate Plus Dexamethasone Under Study in Resistant Myeloma

Pegfilgrastim Versus Filgrastim for Heavily Pretreated Patients With Multiple Myeloma

Adding Daratumumab to Carfilzomib-Based Therapy in Resistant Myeloma: CANDOR Trial

Post-Hoc Analysis of Belantamab Mafodotin in Resistant Myeloma From DREAMM-2

Salvage Therapy Under Study for Resistant Myeloma With Extramedullary Disease

SOHO 2020: Cross-Study Comparison of Carfilzomib, Dexamethasone, and Daratumumab Dosing Regimens in Myeloma

Triplet Regimens Compared in Newly Diagnosed Multiple Myeloma: ENDURANCE Trial

Older Adults With Myeloma: Second Primary Malignancy and Lenalidomide Therapy

Do Diagnostic Pathways Determine Multiple Myeloma Severity?

SOHO 2020: Fixed-Volume Isatuximab in Resistant Multiple Myeloma

Chromosome 1q Abnormalities in Patients With Myeloma: Predictive of Inferior Outcomes?

Transplant-Ineligible Myeloma: Comparing Regimens With and Without Daratumumab

Multiple Myeloma and COVID-19: Treatment Lessons Learned

FDA Brief: Priority Review for Melphalan Flufenamide Combination in Myeloma

Invasive Fungal Infections and Early Mortality in Patients With Multiple Myeloma

Bortezomib-Based Regimens Compared for Myeloma-Related Acute Kidney Injury

Daratumumab Combination Approved by FDA in Resistant Multiple Myeloma

Transplantation for Myeloma: Outcomes for Patients With Clonal Hematopoiesis

Differential Risks for Multiple Myeloma in New York City Neighborhoods

COVID-19 and Myeloma: Continuity of Care in Italian Tertiary Hospital

DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma

FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma

Ongoing Phase III Trial Compares Venetoclax With Standard Therapy for Resistant Myeloma

Vaccinating Against Pneumonia in Patients With Myeloma

AACR COVID-19: Older Patients With Multiple Myeloma at Risk

Subgroup Analysis of Isatuximab-Based Therapy for Resistant Myeloma

AACR COVID-19: Psychosocial Distress Among Patients With Active Myeloma

FDA Advisory Panel Votes in Favor of Approving Belantamab Mafodotin in Myeloma

FDA Accepts Supplemental New Drug Application for Selinexor in Myeloma

EHA25 Virtual: Adding Elotuzumab to Treatment Regimen in Newly Diagnosed Myeloma

FDA New Drug Application Submitted for Triple-Refractory Myeloma Combination Therapy

EHA25 Virtual: Deauville Score Criteria and Minimal Residual Disease in Myeloma

Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma

BELLINI Trial of Venetoclax-Based Combination Therapy in Resistant Myeloma

EHA25 Virtual: Long-Term Follow-up of Early Treatment of Smoldering Multiple Myeloma

EHA25 Virtual: Maintenance Myeloma Therapy With Ixazomib and Without AutoSCT

EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma

ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma

EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma

ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

EHA25 Virtual: BELLINI Trial Update on Venetoclax-Based Regimen in Multiple Myeloma

ASCO20: Long-Term Outcomes With AutoHCT in Multiple Myeloma

ASCO20: Adding Elotuzumab to Bortezomib-Based Therapies for High-Risk Multiple Myeloma

ASCO20: Venetoclax Combination Therapy for Resistant Myeloma